PMID- 35595070
OWN - NLM
STAT- MEDLINE
DCOM- 20231030
LR  - 20231030
IS  - 1879-0631 (Electronic)
IS  - 0024-3205 (Linking)
VI  - 302
DP  - 2022 Aug 1
TI  - Dose-dependent renoprotective impact of Lactoferrin against glycerol-induced 
      rhabdomyolysis and acute kidney injury.
PG  - 120646
LID - S0024-3205(22)00346-0 [pii]
LID - 10.1016/j.lfs.2022.120646 [doi]
AB  - Acute kidney injury (AKI) is a clinical disorder with a serious impact on the 
      quality of patients' lives. Considering its increased worldwide prevalence, 
      investigating novel therapeutic approaches for the management of AKI has been 
      inevitable. Lactoferrin (LF), a glycoprotein belonging to the transferrin family, 
      is known to play an important role in regulating iron homeostasis. This study 
      aimed to evaluate the renoprotective effect of LF (30, 100, and 300 mg/kg orally) 
      against glycerol (GLY)-induced rhabdomyolysis (RM) in rats. RM was induced by a 
      single intramuscular injection of GLY 50% (10 mL/kg) after 24-h water deprivation 
      in male Sprague-Dawley rats. LF administration conferred significant 
      dose-dependent renoprotective impact against GLY-induced RM as evidenced by the 
      decreased renal/somatic index and the significant improvement in renal functions 
      as confirmed by the significant increase in creatinine clearance, decrease in 
      serum creatinine and blood urea nitrogen, and improvement in albuminuria and 
      proteinuria. Redox homeostasis was significantly restored in a dose-dependent 
      manner as well. Moreover, serum interleukin-1beta (IL-1beta) was significantly 
      decreased with a parallel significant decrease in renal NOD-like receptor family 
      pyrin domain containing 3 (NLRP3) and thioredoxin interacting protein (TXNIP), 
      kidney injury molecule-1 (KIM-1), caspase-3 expression, nuclear factor kappa B 
      (NF-kappaB), cluster of differentiation (CD68) expression, and a significant increase 
      in renal nuclear factor erythroid 2-related factor 2 (NRF2) expression. 
      Ultimately, LF administration was associated with a significant amelioration of 
      GLY-induced renal necrotic and inflammatory alterations. In conclusion, the 
      observed dose-dependent nephroprotective effect of LF can be attributed to its 
      modulatory impact on inflammatory/apoptotic/oxidative signaling.
CI  - Copyright (c) 2022 Elsevier Inc. All rights reserved.
FAU - Madkour, Ahmed H
AU  - Madkour AH
AD  - Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura 
      University, 35516 Mansoura, Egypt.
FAU - Helal, Manar G
AU  - Helal MG
AD  - Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura 
      University, 35516 Mansoura, Egypt.
FAU - Said, Eman
AU  - Said E
AD  - Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura 
      University, 35516 Mansoura, Egypt; Faculty of Pharmacy, New Mansoura University, 
      7723730 New Mansoura, Egypt. Electronic address: emansaid@mans.edu.eg.
FAU - Salem, Hatem A
AU  - Salem HA
AD  - Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura 
      University, 35516 Mansoura, Egypt.
LA  - eng
PT  - Journal Article
DEP - 20220517
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
RN  - 0 (Cell Cycle Proteins)
RN  - PDC6A3C0OX (Glycerol)
RN  - EC 3.4.21.- (Lactoferrin)
RN  - 0 (NLR Family, Pyrin Domain-Containing 3 Protein)
RN  - 0 (TXNIP protein, rat)
SB  - IM
MH  - Animals
MH  - Male
MH  - Rats
MH  - *Acute Kidney Injury/chemically induced/drug therapy/prevention & control
MH  - Cell Cycle Proteins/metabolism
MH  - Glycerol/toxicity
MH  - Kidney/metabolism
MH  - Lactoferrin/pharmacology/therapeutic use
MH  - NLR Family, Pyrin Domain-Containing 3 Protein/metabolism
MH  - Oxidative Stress
MH  - Rats, Sprague-Dawley
MH  - *Rhabdomyolysis/chemically induced/complications/drug therapy
OTO - NOTNLM
OT  - Caspase-3
OT  - Glycerol
OT  - Lactoferrin
OT  - NLRP3
OT  - Renoprotection
OT  - TXNIP
EDAT- 2022/05/21 06:00
MHDA- 2023/10/23 12:44
CRDT- 2022/05/20 19:32
PHST- 2022/03/18 00:00 [received]
PHST- 2022/05/11 00:00 [revised]
PHST- 2022/05/12 00:00 [accepted]
PHST- 2023/10/23 12:44 [medline]
PHST- 2022/05/21 06:00 [pubmed]
PHST- 2022/05/20 19:32 [entrez]
AID - S0024-3205(22)00346-0 [pii]
AID - 10.1016/j.lfs.2022.120646 [doi]
PST - ppublish
SO  - Life Sci. 2022 Aug 1;302:120646. doi: 10.1016/j.lfs.2022.120646. Epub 2022 May 
      17.